On August 13, 2026, Heart & Stroke and Brain Canada announced CA$5 million over five years for the RENEW Network — Redesigning Effective and Equitable systems of care for Women's heart-brain recovery — led by Dr. Jodi Edwards of the University of Ottawa Heart Institute and the Bruyère Health Research Institute. Femtech Insider amplified the funding on August 20. It is the third recipient of the partners' Research Network of Excellence in Women's Heart and/or Brain Health program.

Why It Matters

Menopause research has spent 2026 steadily colonizing adjacent specialties, and this is the clearest example yet of it reaching a field with no obvious reproductive framing. Stanford's August 12 autopsy study tied estrogen-only hormone therapy to 35% lower odds of Alzheimer's. AbCellera's ABCL635 posted an 83% reduction in hot flashes in Phase 2 on August 11. TD Bank put $1 million behind a Mount Sinai study of hormone therapy for menopause-related migraine and cognitive symptoms in July. Each treats hormonal status as a systemic variable rather than a niche women's-health topic — and RENEW extends that into how the health system physically routes patients through recovery. For femtech operators, the practical read is about evidence infrastructure. The recurring failure mode in this sector is a product that works but has nowhere to be reimbursed from — Play Health shut down on August 12 with its CEO saying better menopause care "continues to be a 'nice to have.'" Networks like RENEW generate the referral-pattern and outcomes data that eventually justify coverage decisions. It is slower than a funding round and considerably more durable. It is also worth noting who is paying. This is philanthropic and foundation capital, not venture money, following the same pattern as Innovate UK's Women in Innovation grants, the NIH/HeroX maternal health challenge, and the Nordic Next Phase Femtech program. Non-dilutive funding is quietly doing a large share of the women's-health evidence-building that private capital has not been willing to underwrite.

The problem RENEW is built around is a referral gap, not a treatment gap. Women recovering from heart-brain events — stroke, heart attack, cardiac arrest — face delayed access to rehabilitation, lower referral rates, and reduced participation in recovery programs than men. Heart & Stroke's framing is that rehab systems largely do not account for sex-specific recovery factors, naming menopause and mental health explicitly, nor for sociocultural factors including geography, income, ethnicity, disability, and caregiving responsibilities.

That menopause line is the piece with implications beyond cardiology. RENEW will generate new evidence on how menopause, hormone changes, and hormone therapy affect recovery — extending hormonal status from a reproductive-health variable into a rehabilitation-outcomes variable. The network's other stated priorities include mental health support during brain rehabilitation, new rehab and mental health interventions, and referral patterns themselves.

"The RENEW Network represents an important step forward in addressing inequities in rehabilitation and recovery," said Doug Roth, CEO of Heart & Stroke, describing a collaboration bringing together researchers, clinicians, people with lived experience, and health system leaders nationally. Brain Canada president and CEO Viviane Poupon framed the goal as ensuring "the progress we've made in understanding women's brain health translates into better care and recovery after a heart-brain event."

Sources

Update — 2026-08-22

{Initial entry — story first created.}